Tissue engineering technology is of particular import to the Army for the matter of producing tissue replacements for the repair and regeneration of various organ systems (liver, heart, muscle, lung, etc.) for wounded patients. Unfortunately, the production of masses of tissue with thicknesses greater than ~1 mm presents a challenge due to diffusion limits of nutrients into the tissue and waste out of the tissue. This is solved through proper vascularization. Providing vasculature for lab-grown tissues (in addition to providing the correct nutrients, growth factors, etc.) is essential to keeping them alive and functional for any relevant length of time. In order to meet these challenges, Lynntech is proposing the development of a hybrid bioreactor/3D-printing system in order to engineer vascularized skeletal muscle tissue for the treatment of volumetric muscle loss (VML). We will demonstrate feasibility through the production of thick, vascularized skeletal muscle tissue, taking into account QbD principles to develop a pathway to process quality control and scalability. The Phase II development process will include tissue growth optimization, manufacturing and regulatory assessments, and evaluation of functional restorative capabilities engineering muscle through implantation in an animal model of VML.